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Introduction: Approximately 5%-10% of patients with breast cancer have distant 
metastases at first presentation. Chemotherapy or hormone therapy  is often the 
main treatment in these patients without loco-regional treatment (surgery or 
radiotherapy) except in cases of fungation forms and bleeding. There are studies 
that have shown that removal of primary tumor at  times leads to complete 
disappearance of metastases and improvement in survival in renal cell carcinoma 
patients. However, such studies have never been performed in other solid tumors. 
On the other hand, there is a strong body of evidence in experimental settings 
showing  that removal of primary tumor allows growth of metastasis. There is lack of 
similar data in humans in clinical settings. Breast cancer as a biological and 
genetically heterogeneous tumor often metastasizes to the bone so patients with 
bone metastases form the largest group of patients with metastatic disease. The 
incidence is significantly high in steroid receptor positive tumors and well-
differentiated lesions. Approximately 50% of patients with metastatic bone disease 
have clinical symptoms, and in 4% -7% develop pathological fractures of the long 
bones. Patients with bone metastases from breast cancer are with better survival 
than from other tumors. Recent data suggest that survival may be improved if 
disease is controlled by offering loco-regional treatment of the primary tumor in 
metastatic breast cancer. This a case report about 44 years old femail patient with 
breast cancer with diffuse bone metastases at first presentation. 
 
Diagnostic considerations: The patient came to the Clinic of oncology and 
radiotherapy in March 2005  for further treatment with the diagnosis: Carcinoma 
metastaticum vertebrae lumbosacralis  proven by CT stereotactic biopsy of L5.The 
patient has done the following tests:1. scan of skeleton: metastatic deposits in spine, 
rib 7 and 10, manubrium sterni and sacrum; 2. mammography findings were with the 
presence of malignancy ( 20,5x13 mm)  in left breast with package lymph nodes in 
the left aksila;3. FNAB of the breast: was  without  the presence of malignant cells 
but from the lymph node of aksila: deposit of breast cancer. In the context of this 
patient's clinical stage was: T2N1M1 Gx (Stg. IV). Immunohistochemical findings of 
metastasis in the vertebra was: HER: -; ER: 2+/3+ ; PGR: unconclusive.  CEA=9,71 
ng/ml; CA15-3: 22,2U/ml. 
 
Treatment: Initial treatment 2005.: 6 cycles of chemotherapy ( AC protocol - 
Doxorubicin 60mg/m2 + Cyclophosphamid 600mg/m2  i.v  at 21 days ) + 
bisphosphonate therapy (amp.Pamidronic acid a 90mg, iv , at  28 days) + realised 
radiotherapy on  L5, TTD = 30Gy, 10fr/3Gy, TCT. Tumor markers at the end of 
treatment: CEA: 2,38; CA15-3: 19.6.  After that a radical mastectomy of the left  
breast with dissection of left aksila was conducted and an immunohistochemistry 
from the breast was: HER: "-", ER: "-", PGR: "-". The patient was set on hormone 
therapy : Tabl.Tamoxifen a 10 mg 2x1. In June 2007 patient is started with second-
line hormone therapy because for the growth of tumor marker (CEA = 17,7), 
progress of metastatic disease and menopause (Aromatase inhibitor - Tabl.Letrozol 
1x1). November 2010 due to the progress of bony metastases of the thoracic spine 
and inability for radyotherapy due to cumulative toxicity of spinal cords from previous 
radiotherapy to the thoracic spine , bisphosphonate therapy was changed. ( 
amp.Zolendronic acid a 4mg i.v ). 
 
Results /Follow-up: 2006-2010: The patient  was in good general condition. 
Continues with intravenous bisphosphonate therapy for 28 days and hormone 
therapy. Ultrasonography of the breast every 6 months: normal findings. 
Mammography annually: normal finding. Abdominal echo every 6 months: normal 
findings. X-rays of the lungs annually: normal findings. Tumor markers every 6 
months: in reference. Sken of the skeleton once a year: the appearance of 
metastases on both shoulders and right art. sacro-iliaca, whole thoracic and lumbar 
spine (2007), left clavicle (2008), the progress of the thoracic spine(2010). 
2011-2013: Good general condition. Stable metastatic disease. The patient is still on 
bisphosphonates and hormone therapy. Scan skeleton: Regression of bone 
metastases. Eight-year survival. 
 
Conclusion: Some of the patients who present with breast cancer already have 
distant metastatic disease. According to recent literature, these patients may benefit 
from resection of the breast tumour. One explanation for the effect of this resection is 
that reducing the tumour load influences metastatic growth. When metastasectomy is 
not possible, minimally invasive techniques can be used in selected patients for the 
treatment of breast cancer liver metastases, radiofrequency ablation (RFA) being 
discussed most in the literature. Results of future randomised controlled trials should 
indicate whether surgery of the breast tumour truly improves survival and is there 
any differences between initially bone and parenchymal metastases.  
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